489 related articles for article (PubMed ID: 33882378)
1. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
2. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
7. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Guigay J; Le Caer H; Ferrand FR; Geoffrois L; Saada-Bouzid E; Fayette J; Sire C; Cupissol D; Blot E; Guillet P; Pavillet J; Bozec L; Capitain O; Rolland F; Debourdeau P; Pointreau Y; Falandry C; Lopez S; Coutte A; Chatellier T; Dalloz P; Ortholan C; Michel C; Lacas B; Cheurfa N; Schwob D; Bourhis J; Mertens C; Aupérin A;
Lancet Healthy Longev; 2024 Jun; 5(6):e392-e405. PubMed ID: 38759667
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
9. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
12. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
13. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
Bernad IP; Trufero JM; Urquizu LC; Pazo Cid RA; de Miguel AC; Agustin MJ; Lanzuela M; Antón A
Clin Transl Oncol; 2017 Jun; 19(6):769-776. PubMed ID: 28120324
[TBL] [Abstract][Full Text] [Related]
14. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.
Surmeli ZG; Ozveren A; Arslan C; Degirmenci M; Karaca B; Uslu R
Indian J Cancer; 2019; 56(1):4-8. PubMed ID: 30950435
[TBL] [Abstract][Full Text] [Related]
15. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
[TBL] [Abstract][Full Text] [Related]
16. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
19. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
